- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06371040
Safety and Efficacy of CD19-BCMA Targeted CAR-T Therapy for Refractory Generalized Myasthenia Gravis
Evaluate the Safety and Efficacy of CD19-BCMA Targeted CAR-T Therapy for Refractory, Generalized Myasthenia Gravis: A Single-center, Open-label, Single-arm, Dose-finding Study
Study Overview
Status
Conditions
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Shaanxi
-
Xi'an, Shaanxi, China, 710038
- Tangdu Hospital, The Fourth Military Medical University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Study participants will be selected for this study only if they meet all of the following criteria:
- Age ≥18 years old and ≤80 years old;
- The subject signs the informed consent form, is willing and able to comply with the protocol, complete the research assessment and return for follow-up;
- To be diagnosed as a patient with systemic MG, the patient is required to have positive myasthenia-related antibodies (AChR-Ab, Musk-Ab or LRP4) on the basis of typical myasthenic symptoms;
Evaluated by the researcher as refractory MG. Refractory MG is defined as:
- Treatment failed after receiving at least 2 immunosuppressants
- Definition of treatment failure: 1) Persistent weakness and impairment of daily activities; 2) MG aggravation and/or crisis during treatment; 3) Intolerance to immunotherapy due to side effects or comorbidities;
- Repeated plasma exchange (PE) or intravenous immune globulin (IVIg) treatment is required to control symptoms;
- The researchers believe that despite the current routine immunotherapy for patients, MG still imposes a large functional burden on patients.
- MGFA classification IIa~IVa at screening and baseline;
- QMGS score ≥11 points or MG-ADL score ≥5 points at screening and baseline, of which the eye score accounts for no more than 50%;
- Male study participants must agree to take contraceptive measures during the treatment period and within 1 year after receiving study treatment, and are prohibited from donating sperm throughout the study period;
- If you are a woman of childbearing potential (WOCBP), you must agree to take contraceptive measures during treatment and for at least 1 year after receiving study treatment. Participants must have a negative serum pregnancy test result during screening; a negative urine pregnancy test result must be confirmed before receiving CART for the first time.
Exclusion Criteria:
Prior to screening and the baseline visit, study participants will not be eligible for inclusion in the study if they meet any of the following criteria:
- The researcher believes that there is any medical or mental condition that may harm the research participant or affect the research participant's ability to participate in this study; or any condition that the researcher believes is related to poor compliance;
- Women who are lactating or pregnant, or women who plan to become pregnant at any time within 12 months after receiving CART treatment, or who have a history of spontaneous abortion or induced abortion within 4 weeks before screening;
- Study participants have clinically relevant active infections (such as sepsis, pneumonia or abscess) or serious infections (resulting in hospitalization or requiring antibiotic treatment) within 4 weeks before screening;
- thymoma that underwent thymectomy within 6 months before baseline or was planned to undergo thymectomy during the study, or required chemotherapy and/or radiotherapy at any time;
- Investigator participants have received live attenuated vaccine vaccination within 8 weeks before screening; or plan to receive live vaccine vaccination within 8 weeks after treatment;
- Study participants have received rituximab treatment within 6 months before screening;
- Have received tocilizumab or eculizumab treatment within 3 months before screening;
- Have received intravenous human immunoglobulin, plasma exchange, or immunotherapy within 4 weeks before screening;
- Those with known serious underlying diseases, such as liver and kidney damage, blood diseases, previous severe cardiovascular disease, severe hypertension, diabetes, and poor blood pressure and blood sugar control;
- Unresected thymoma (Note: Subjects with benign thymoma resected more than one year before screening are eligible. Benign is defined as no known metastasis on pathological examination and no intracystic or extracystic Extension. Imaging studies must be performed during the screening period to assess thymic status).
Any of the following laboratory abnormalities occur during the screening period (one repeat measurement can be performed during the screening period before randomization to confirm the results)
- Elevated liver enzymes (aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 times the upper limit of normal (ULN)).
- Total bilirubin>1.5 times ULN
- Estimated glomerular filtration rate (eGFR) <45 mL/min/1.73 m2
- Abnormal PT or INR, or prolonged APTT >1.5 times ULN
- Neutrophil count <1000cell/ul
- Platelet count <50000/mm3
- Hemoglobin<8.0g/dl
- Those with a high-risk history of tuberculosis infection or acquired tuberculosis infection;
- Known immunodeficiency diseases, including human immunodeficiency virus (HIV) infection;
- Positive for hepatitis B surface antigen (HBsAg) during the screening period;
- Receive blood transfusion treatment 4 weeks before screening or during the screening period;
- Symptoms worsen rapidly during the lead-in period and enter crisis or pre-crisis state (MGFA IVb-V)
- Other circumstances in which the researcher deems it inappropriate to participate in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CD19-BCMA Targeted CAR-T
|
5.0 e5/ kg CD19-BCMA CAR-T positive T cells
1.5 e6/ kg CD19-BCMA CAR-T positive T cells
5 e6/ kg CD19-BCMA CAR-T positive T cells
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequency, type, and severity of adverse events
Time Frame: From Baseline (Day 1) to Safety Follow-Up Visit (up to 4 weeks)
|
Frequency, type, and severity of adverse events (according to the National Cancer Institute Common Terminology Criteria for Adverse Events CTCAE V5.0) occurring within 4 weeks after CD19-BCMA CAR-T infusion
|
From Baseline (Day 1) to Safety Follow-Up Visit (up to 4 weeks)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequency, type, and severity of abnormal laboratory indicators related to treatment
Time Frame: From Baseline (Day 1) up fo Follow-Up (up to 24 weeks)
|
Frequency, type, and severity of abnormal laboratory indicators related to treatment (according to the National Cancer Institute Common Terminology Criteria for Adverse Events CTCAE V5.0)
|
From Baseline (Day 1) up fo Follow-Up (up to 24 weeks)
|
Changes of blood pressure
Time Frame: From Baseline (Day 1) up fo Follow-Up (up to 24 weeks)
|
From Baseline (Day 1) up fo Follow-Up (up to 24 weeks)
|
|
Changes of pulse rate
Time Frame: From Baseline (Day 1) up fo Follow-Up (up to 24 weeks)
|
From Baseline (Day 1) up fo Follow-Up (up to 24 weeks)
|
|
Changes of weight
Time Frame: From Baseline (Day 1) up fo Follow-Up (up to 24 weeks)
|
From Baseline (Day 1) up fo Follow-Up (up to 24 weeks)
|
|
Changes of Myasthenia Gravis Activities of Daily Living (MG-ADL) scores
Time Frame: From Baseline (Day 1) up fo Follow-Up (up to 24 weeks)
|
Changes in MG-ADL scores [0-24 point] from baseline at 24 weeks after CD19-BCMA CAR-T infusion
|
From Baseline (Day 1) up fo Follow-Up (up to 24 weeks)
|
Changes of Quantitative Myasthenia Gravis (QMG) scores
Time Frame: From Baseline (Day 1) up fo Follow-Up (up to 24 weeks)
|
Changes in QMG scores [0-39 point] from baseline at 24 weeks after CD19-BCMA CAR-T infusion
|
From Baseline (Day 1) up fo Follow-Up (up to 24 weeks)
|
Changes of Myasthenia Gravis Composite (MGC) scores
Time Frame: From Baseline (Day 1) up fo Follow-Up (up to 24 weeks)
|
Changes in MGC scores [0-50 point] from baseline at 24 weeks after CD19-BCMA CAR-T infusion
|
From Baseline (Day 1) up fo Follow-Up (up to 24 weeks)
|
Proportion of subjects who achieved improvement
Time Frame: From Baseline (Day 1) up fo Follow-Up (up to 24 weeks)
|
Proportion of subjects who achieved improvement at 24 weeks after CD19-BCMA CAR-T infusion and sustained it for at least 4 weeks (clinical improvement difined as a ≥2-point reduction in the total MG-ADL score [0-24 point])
|
From Baseline (Day 1) up fo Follow-Up (up to 24 weeks)
|
Time to achieve clinical improvement
Time Frame: From Baseline (Day 1) up fo Follow-Up (up to 24 weeks)
|
Time to achieve clinical improvement (clinical improvement difined as a ≥2-point reduction in the total MG-ADL score [0-24 point])
|
From Baseline (Day 1) up fo Follow-Up (up to 24 weeks)
|
Changes of myasthenia gravis-specific autoantibody titers
Time Frame: From Baseline (Day 1) up fo Follow-Up (up to 24 weeks)
|
Changes from baseline in myasthenia gravis-specific autoantibody titers over 24 weeks after CD19-BCMA CAR-T infusion
|
From Baseline (Day 1) up fo Follow-Up (up to 24 weeks)
|
Changes of immunoglobulins
Time Frame: From Baseline (Day 1) up fo Follow-Up (up to 24 weeks)
|
Changes in immunoglobulins (IgG, IgM, IgA, IgE) within 24 weeks after CD19-BCMA CAR-T infusion
|
From Baseline (Day 1) up fo Follow-Up (up to 24 weeks)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in proportion of peripheral blood immune cell
Time Frame: From Baseline (Day 1) up fo Follow-Up (up to 24 weeks)
|
Changes in proportion of peripheral blood immune cell subsets of subjects after infusion of CD19-BCMA CAR-T
|
From Baseline (Day 1) up fo Follow-Up (up to 24 weeks)
|
serum inflammatory markers levels
Time Frame: From Baseline (Day 1) up fo Follow-Up (up to 4 weeks)
|
The levels of biomarkers used to evaluate safety and efficacy after infusion of CD19-BCMA CAR-T (ie, serum cytokine levels, serum inflammatory markers, plasma BCMA levels).
Cytokines include at least IFNγ, IL-6, Soluble gp130, soluble IL-6R, TNFα, IL-2 and IL-10, other biomarkers and cytokines will be added based on the literature
|
From Baseline (Day 1) up fo Follow-Up (up to 4 weeks)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Nervous System Diseases
- Immune System Diseases
- Neoplasms
- Autoimmune Diseases of the Nervous System
- Autoimmune Diseases
- Neoplasms by Site
- Neurologic Manifestations
- Musculoskeletal Diseases
- Muscular Diseases
- Neuromuscular Diseases
- Neurodegenerative Diseases
- Neuromuscular Manifestations
- Nervous System Neoplasms
- Paraneoplastic Syndromes, Nervous System
- Paraneoplastic Syndromes
- Neuromuscular Junction Diseases
- Muscle Weakness
- Myasthenia Gravis
Other Study ID Numbers
- V1.0, CART-20230619
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Supporting Information Type
- ANALYTIC_CODE
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myasthenia Gravis
-
Assiut UniversityRecruitingNervous System Diseases | Autoimmune Diseases of the Nervous System | Thymoma | Myasthenia Gravis | Neuromuscular Junction Diseases | Myasthenia Gravis, Generalized | Myasthenia Gravis Crisis | Myasthenia Gravis, Ocular | Myasthenia Gravis, Juvenile Form | Thymus Hyperplasia | Myasthenia Gravis With Exacerbation... and other conditionsEgypt
-
Universiti Putra MalaysiaEnrolling by invitationExperimental MyastheniaChina
-
Universiti Putra MalaysiaCompletedExperimental MyastheniaChina
-
Alexion Pharmaceuticals, Inc.CompletedMyasthenia Gravis | Myasthenia Gravis, Generalized | Myasthenia Gravis, Juvenile FormUnited States, Japan, Netherlands
-
COUR Pharmaceutical Development Company, Inc.RecruitingMyasthenia Gravis | Generalized Myasthenia | AChR Myasthenia Gravis | MuSK MGUnited States
-
Catalyst Pharmaceuticals, Inc.CompletedMyasthenia Gravis, GeneralizedUnited States
-
Instituto Nacional de Ciencias Medicas y Nutricion...CompletedMyasthenia Gravis, Thymectomy
-
Fondation Ophtalmologique Adolphe de RothschildCompleted
-
argenxNot yet recruitingGeneralized Myasthenia Gravis
-
Cabaletta BioNot yet recruitingGeneralized Myasthenia Gravis (gMG)
Clinical Trials on CD19-BCMA Targeted CAR-T Dose 1
-
Zhejiang UniversityYake Biotechnology Ltd.RecruitingAcute Lymphoblastic Leukemia, in Relapse | Multiple Myeloma in Relapse | Multiple Myeloma, Refractory | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma Refractory | Acute Lymphocytic Leukaemia RefractoryChina
-
Zhejiang UniversityYake Biotechnology Ltd.RecruitingVasculitis | Amyloidosis | Autoimmune Hemolytic Anemia | POEMS SyndromeChina
-
Zhejiang UniversityYake Biotechnology Ltd.RecruitingRefractory Multiple Myeloma | Relapse Multiple MyelomaChina
-
Zhejiang UniversityYake Biotechnology Ltd.Not yet recruitingRefractory Multiple Myeloma | Relapse Multiple MyelomaChina
-
University College, LondonEnrolling by invitationMultiple MyelomaUnited Kingdom
-
Southwest Hospital, ChinaUnknownLymphoma | Leukemia | Multiple MyelomaChina
-
Hrain Biotechnology Co., Ltd.First Affiliated Hospital of Wenzhou Medical University; Shanghai Changzheng...Recruiting
-
Wuhan Union Hospital, ChinaNot yet recruitingMultiple Myeloma
-
Zhejiang UniversityShanghai YaKe Biotechnology Ltd.Recruiting
-
Zhejiang UniversityShanghai YaKe Biotechnology Ltd.Not yet recruitingNon-hodgkin Lymphoma,B Cell | Acute Lymphoblastic Leukemia,B-CellChina